AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 APR 4 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Vaccination against Lyme disease is safe and effective. The question is, can it be justified in economic terms?
The answer appears to be yes - if an area is endemic for the parasitic infection.
Researchers investigated whether the cost of large-scale Lyme disease vaccination is worthwhile in terms of quality of life gained due to disease avoidance.
"We developed a decision-analytic model to evaluate the cost-effectiveness of vaccination compared with no vaccination in individuals living in endemic areas of Lyme disease," reported N.A. Shadick and colleagues at Brigham and Women's Hospital, Massachusetts, in the Archives of Internal Medicine.
They evaluated the cost of the vaccine per quality-adjusted life-year (QALY) gained from disease avoidance over a 10-year period, using weights specific to Lyme disease symptoms and complications.
Their model concluded that vaccinating 10,000 people living in areas where Lyme disease probability was 1% resulted in averting 202 cases of Lyme disease over 10 years, at a cost of $62,300 per QALY ("The cost-effectiveness of vaccination against Lyme disease," Arch Intern Med, 2001;161(4):554-561).